Waters Purification Solutions

Article

Waters' robust purification solutions are flexible, scalable, and easily integrated.

Waters announces the Prep 150 LC System, a new fit-for-purpose preparative chromatography system designed to isolate target compounds from crude mixtures synthesized in the laboratory or extracted from natural sources during initial purification processes.

"With this system we are responding to requests from scientists for a robust, reliable and dedicated personal chromatography system that can manage the occasional or everyday purification needs of scientists at the bench," said Wendy Harrop, Product Manager, Waters Division. "The introduction of this system demonstrates Waters commitment to serve the needs of scientists not only for analytical-scale LC but for preparative-scale purification as well."

Based on innovative high performance liquid chromatography (HPLC) hardware and software, the Waters Prep 150 LC System features ChromScope™ Software intended for scientists and technicians of all skill levels - from novice to expert - with minimal training. This dedicated HPLC system enables chemists to purify and capture quantities of specific molecular entities as part of their research into new drugs, natural products, and specialty chemicals.

The Waters Prep 150 LC System operates at flow rate ranges of up to 150 mL/min. and features options for detection, sample injection, and solvent delivery systems in order to better suit specific application needs. The Prep 150 LC is supported with a full complement of scalable Waters OBD™ preparative 10 to 50 mm (I.D.) Columns featuring 5 to 10 micron chemistries.

Recent Videos
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Related Content